{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:06:07Z","timestamp":1769850367734,"version":"3.49.0"},"reference-count":58,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"publisher","award":["TCRD-TPE-110-023 (2\/3)"],"award-info":[{"award-number":["TCRD-TPE-110-023 (2\/3)"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Although neurological complications after the administration of vaccines against coronavirus disease 2019 (COVID-19) are rare, they might result in long-term morbidity. This study was designed to determine the risk of peripheral nervous system (PNS) adverse events after the administration of mRNA vaccines against COVID-19. Large-scale randomized controlled trials (RCTs) and cohort studies were systematically searched in databases, and 15 cohort studies were included in the synthesis. Among all PNS adverse events, only Bell\u2019s palsy and Guillain\u2013Barr\u00e9 syndrome (GBS) had sufficient data and were included for further analysis. Individuals who received mRNA vaccines had a higher risk of Bell\u2019s palsy than the unvaccinated group, and the risk of Bell\u2019s palsy after BNT162b2 was significantly higher than after mRNA-1273. Regarding GBS, no significant difference in the risk was observed between BNT162b2 and the unvaccinated group, but BNT126b2 introduced a higher risk of post-vaccinated GBS than mRNA-1273. In conclusion, PNS adverse events, especially Bell\u2019s palsy, should be carefully observed after mRNA vaccination against COVID-19. With the opportunity of vaccination campaigns on such a large scale, further investigation and surveillance of post-vaccination neurological adverse events should also be established.<\/jats:p>","DOI":"10.3390\/vaccines10122174","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T06:24:44Z","timestamp":1671431084000},"page":"2174","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peripheral Nervous System Adverse Events after the Administration of mRNA Vaccines: A Systematic Review and Meta-Analysis of Large-Scale Studies"],"prefix":"10.3390","volume":"10","author":[{"given":"Yu-Hsin","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Taipei Tzu Chi Hospital, Tzu Chi Medical Foundation, New Taipei 231405, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Taipei Tzu Chi Hospital, Tzu Chi Medical Foundation, New Taipei 231405, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Hui","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taipei Tzu Chi Hospital, Tzu Chi Medical Foundation, New Taipei 231405, Taiwan"},{"name":"School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8244-2846","authenticated-orcid":false,"given":"Yi-No","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taipei Tzu Chi Hospital, Tzu Chi Medical Foundation, New Taipei 231405, Taiwan"},{"name":"Cochrane Taiwan, Taipei Medical University, Taipei 11031, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Bing","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taipei Tzu Chi Hospital, Tzu Chi Medical Foundation, New Taipei 231405, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien 97004, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/d41586-022-00104-8","article-title":"The pandemic\u2019s true death toll: Millions more than official counts","volume":"601","author":"Adam","year":"2022","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(21)02226-1","article-title":"Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: An ecological analysis of national surveillance data","volume":"399","author":"Burke","year":"2022","journal-title":"Lancet"},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration (2021). FDA Approves First COVID-19 Vaccine."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Shefner, J.M. (2022). COVID-19: Vaccines: UpToDate, UpToDate.","DOI":"10.1097\/01.ASM.0000911752.19079.af"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106694","DOI":"10.1016\/j.ypmed.2021.106694","article-title":"Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors","volume":"150","author":"Wang","year":"2021","journal-title":"Prev. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijid.2021.08.071","article-title":"Facial nerve palsy following the administration of COVID-19 mRNA vaccines: Analysis of a self-reporting database","volume":"111","author":"Sato","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e04756","DOI":"10.1002\/ccr3.4756","article-title":"COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect","volume":"9","author":"Matarneh","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ana.26218","article-title":"Guillain-Barr\u00e9 Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines","volume":"90","author":"Osowicki","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s42399-022-01124-1","article-title":"Sub-acute Onset of Guillain-Barr\u00e9 Syndrome Post-mRNA-1273 Vaccination: A Case Report","volume":"4","author":"Nagalli","year":"2022","journal-title":"SN Compr. Clin. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1473-3099(21)00076-1","article-title":"Bell\u2019s palsy and SARS-CoV-2 vaccines","volume":"21","author":"Ozonoff","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmi.2021.09.018","article-title":"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: Historical cohort study","volume":"28","author":"Shasha","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, Wiley.","DOI":"10.1002\/9781119536604"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11910-021-01102-5","article-title":"Peripheral Nervous System Manifestations Associated with COVID-19","volume":"21","author":"Andalib","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of Facial Paralysis with mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database","volume":"181","author":"Renoud","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","first-page":"965.e5","article-title":"Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines","volume":"2","author":"McMurry","year":"2021","journal-title":"Med (New York)"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1016\/j.vaccine.2021.05.088","article-title":"Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents","volume":"39","author":"Bardenheier","year":"2021","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108786","DOI":"10.1016\/j.clim.2021.108786","article-title":"Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study","volume":"229","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Keh, R.Y.S., Scanlon, S., Datta-Nemdharry, P., Donegan, K., Cavanagh, S., Foster, M., Skelland, D., Palmer, J., Machado, P.M., and Keddie, S. (2022). COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: Analyses using the National Immunoglobulin Database. Brain, Online ahead of print.","DOI":"10.1101\/2021.12.14.21267418"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120030","DOI":"10.1016\/j.jns.2021.120030","article-title":"Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines","volume":"430","author":"Koh","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e068373","DOI":"10.1136\/bmj-2021-068373","article-title":"Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: Population based cohort and self-controlled case series analysis","volume":"376","author":"Li","year":"2022","journal-title":"Bmj"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: An observational study of reports to the Vaccine Adverse Event Reporting System and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1016\/j.vaccine.2022.06.010","article-title":"Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform","volume":"40","author":"Walker","year":"2022","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s00415-019-09282-4","article-title":"The etiology of Bell\u2019s palsy: A review","volume":"267","author":"Zhang","year":"2020","journal-title":"J. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","article-title":"Bell\u2019s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: A case series and nested case-control study","volume":"22","author":"Wan","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.molmed.2017.01.006","article-title":"Type I Interferons Modulate CD8(+) T Cell Immunity to mRNA Vaccines","volume":"23","author":"Grooten","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archotol.1989.01860250039022","article-title":"Elevated serum interferon levels in patients with Bell\u2019s palsy","volume":"115","author":"Jonsson","year":"1989","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/jir.2005.25.174","article-title":"Bell\u2019s palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection","volume":"25","author":"Hoare","year":"2005","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1023\/B:DDAS.0000026389.56819.0c","article-title":"Bell\u2019s palsy: A rare complication of interferon therapy for hepatitis C","volume":"49","author":"Hwang","year":"2004","journal-title":"Dig. Dis. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1046\/j.1365-2516.2000.00391.x","article-title":"Bell\u2019s palsy during interferon therapy for chronic hepatitis C infection in patients with haemorrhagic disorders","volume":"6","author":"Ogundipe","year":"2000","journal-title":"Haemophilia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"n1435","DOI":"10.1136\/bmj.n1435","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-510X(02)00049-7","article-title":"Serum cytokine levels in bell\u2019s palsy","volume":"197","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"604089","DOI":"10.3389\/fpubh.2020.604089","article-title":"Public Health Interventions for the COVID-19 Pandemic Reduce Respiratory Tract Infection-Related Visits at Pediatric Emergency Departments in Taiwan","volume":"8","author":"Lin","year":"2020","journal-title":"Front. Public Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajem.2021.01.065","article-title":"The impact of COVID-19 lockdown on infectious diseases epidemiology: The experience of a tertiary Italian Pediatric Emergency Department","volume":"43","author":"Rotulo","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamaoto.2021.1266","article-title":"Incidence of Bell Palsy in Patients with COVID-19","volume":"147","author":"Tamaki","year":"2021","journal-title":"JAMA Otolaryngol.\u2013Head Neck Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1001\/jama.2021.18504","article-title":"Bell Palsy","volume":"326","author":"Kline","year":"2021","journal-title":"JAMA"},{"key":"ref_48","first-page":"447","article-title":"Bell\u2019s Palsy","volume":"23","author":"Reich","year":"2017","journal-title":"Continuum (Minneap Minn)"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100236","DOI":"10.1016\/j.lanepe.2021.100236","article-title":"Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell\u2019s palsy: A population-based study","volume":"11","author":"Shibli","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 Syndrome following ChAdOx1-S\/nCoV-19 Vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1111\/ene.14860","article-title":"Prevalence, clinical characteristics and outcomes of Guillain-Barr\u00e9 syndrome spectrum associated with COVID-19: A systematic review and meta-analysis","volume":"28","author":"Palaiodimou","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamainternmed.2022.2109","article-title":"Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans","volume":"182","author":"Dickerman","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2124331","DOI":"10.1001\/jamanetworkopen.2021.24331","article-title":"Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine","volume":"4","author":"Richards","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000065645","article-title":"Annualized incidence and spectrum of illness from an outbreak investigation of Bell\u2019s palsy","volume":"21","author":"Morris","year":"2002","journal-title":"Neuroepidemiology"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2174\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:43:21Z","timestamp":1760147001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122174"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122174","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]}}}